



20 May 2025

**Immupharma PLC**  
("Immupharma" or the "Company")

**Notice of AGM & Annual Report & Accounts**

Immupharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, confirms that the Notice of Annual General Meeting ("AGM") has today been posted to shareholders. The Annual Report and Accounts for the year ended 31 December 2024 has also been posted to shareholders today.

These documents will be available shortly, in electronic form, for download on the Company's website [www.immupharma.co.uk](http://www.immupharma.co.uk).

Immupharma's AGM will be held on Thursday 12<sup>th</sup> June 2025 @ 11:00am (BST) at: The Malmaison Hotel, 18-21 Charterhouse Square, Barbican, London EC1M 6AH.

Ends

For further information please contact:

|  |                       |
|--|-----------------------|
| <b>Immupharma PLC</b> ( <a href="http://www.immupharma.com">www.immupharma.com</a> ) | + 44 (0) 207 206 2650 |
| Tim McCarthy, Chairman and Chief Executive Officer                                   |                       |
| Lisa Baderoon, Head of Investor Relations  | + 44 (0) 7721 413496  |
| <b>SPARK Advisory Partners Limited (NOMAD)</b>                                       |                       |
| Neil Baldwin   | +44 (0) 203 368 3550  |
| <b>Stanford Capital Partners (Joint Broker)</b>                                      |                       |
| Patrick Claridge, Bob Pountney   | +44 (0) 203 815 8880  |
| <b>SI Capital (Joint Broker)</b>   |                       |
| Nick Emerson   | +44 (0) 1483 413500   |

**Notes to Editors**

**About Immupharma PLC**

Immupharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases.

For additional information about Immupharma please visit [www.immupharma.co.uk](http://www.immupharma.co.uk)

Immupharma's LEI (Legal Entity Identifier) code: 213800VZKGHC7VUS895

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAGPUWCAUPAUMR